Subscribe

Risk Factors of Olszewski et al for 30-Day Mortality in an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL) After Rituximab-Based Immunochemotherapy

Specialty:

Hematology Oncology

Objective:

ICD-10:

Description:

Olszewski et al identified risk factors for 30-day mortality in older adults with diffuse large B-cell lymphoma (DLBCL) after rituximab-based immunochemotherapy. These can help to identify a patient who may benefit from more aggressive management or an alternative therapeutic strategy. The authors are from Brown University, Rhode Island Hospital, Dana-Farber Cancer Institute and Harvard Medical School.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone